Past decline versus current EGFR and subsequent ESRD risk

Csaba Kovesdy, Josef Coresh, Shoshana H. Ballew, Mark Woodward, Adeera Levin, David M.J. Naimark, Joseph Nally, Dietrich Rothenbacher, Benedicte Stengel, Kunitoshi Iseki, Kunihiro Matsushita, Andrew S. Levey

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

EGFRis a robustpredictor ofESRDrisk.However, the prognostic informationgainedfromthepast trajectory (slope) beyondthat of the currentEGFRisunclear.Weexamined22cohorts todeterminethe associationofpast slopes and current EGFR level with subsequent ESRD. We modeled hazard ratios as a spline function of slopes, adjusting for demographic variables,EGFR,andcomorbidities.Weusedrandomeffectsmeta-analyses tocombineresults across studies stratified by cohort type.We calculated the absolute risk of ESRD at 5 years after the last EGFR using the weighted average baseline risk. Overall, 1,080,223 participants experienced 5163 ESRD events during a mean follow-up of 2.0 years. InCKDcohorts, a slope of26versus0ml/minper 1.73m2 per year over the previous 3 years (adeclineof 18ml/minper1.73m2 versus no decline) associated with an adjusted hazard ratio of ESRDof 2.28 (95% confidence interval, 1.88 to 2.76). In contrast, a current EGFR of 30 versus 50 ml/min per 1.73m2 (a difference of 20 ml/min per 1.73 m2) associated with an adjusted hazard ratio of 19.9 (95% confidence interval, 13.6 to 29.1). Past decline contributed more to the absolute risk of ESRD at lower than higher levels of current EGFR. In conclusion, during a follow-up of 2 years, current EGFR associates more strongly with future ESRD risk than the magnitude of past EGFR decline, but both contribute substantially to the risk of ESRD, especially at EGFR,30ml/min per 1.73m2.

Original languageEnglish (US)
Pages (from-to)2447-2455
Number of pages9
JournalJournal of the American Society of Nephrology
Volume27
Issue number8
DOIs
StatePublished - Jan 1 2016

Fingerprint

Chronic Kidney Failure
Confidence Intervals
Cohort Studies
Demography

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Kovesdy, C., Coresh, J., Ballew, S. H., Woodward, M., Levin, A., Naimark, D. M. J., ... Levey, A. S. (2016). Past decline versus current EGFR and subsequent ESRD risk. Journal of the American Society of Nephrology, 27(8), 2447-2455. https://doi.org/10.1681/ASN.2015060687

Past decline versus current EGFR and subsequent ESRD risk. / Kovesdy, Csaba; Coresh, Josef; Ballew, Shoshana H.; Woodward, Mark; Levin, Adeera; Naimark, David M.J.; Nally, Joseph; Rothenbacher, Dietrich; Stengel, Benedicte; Iseki, Kunitoshi; Matsushita, Kunihiro; Levey, Andrew S.

In: Journal of the American Society of Nephrology, Vol. 27, No. 8, 01.01.2016, p. 2447-2455.

Research output: Contribution to journalArticle

Kovesdy, C, Coresh, J, Ballew, SH, Woodward, M, Levin, A, Naimark, DMJ, Nally, J, Rothenbacher, D, Stengel, B, Iseki, K, Matsushita, K & Levey, AS 2016, 'Past decline versus current EGFR and subsequent ESRD risk', Journal of the American Society of Nephrology, vol. 27, no. 8, pp. 2447-2455. https://doi.org/10.1681/ASN.2015060687
Kovesdy, Csaba ; Coresh, Josef ; Ballew, Shoshana H. ; Woodward, Mark ; Levin, Adeera ; Naimark, David M.J. ; Nally, Joseph ; Rothenbacher, Dietrich ; Stengel, Benedicte ; Iseki, Kunitoshi ; Matsushita, Kunihiro ; Levey, Andrew S. / Past decline versus current EGFR and subsequent ESRD risk. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 8. pp. 2447-2455.
@article{494c5ed4d5f441cd9e9b2050dddb4c79,
title = "Past decline versus current EGFR and subsequent ESRD risk",
abstract = "EGFRis a robustpredictor ofESRDrisk.However, the prognostic informationgainedfromthepast trajectory (slope) beyondthat of the currentEGFRisunclear.Weexamined22cohorts todeterminethe associationofpast slopes and current EGFR level with subsequent ESRD. We modeled hazard ratios as a spline function of slopes, adjusting for demographic variables,EGFR,andcomorbidities.Weusedrandomeffectsmeta-analyses tocombineresults across studies stratified by cohort type.We calculated the absolute risk of ESRD at 5 years after the last EGFR using the weighted average baseline risk. Overall, 1,080,223 participants experienced 5163 ESRD events during a mean follow-up of 2.0 years. InCKDcohorts, a slope of26versus0ml/minper 1.73m2 per year over the previous 3 years (adeclineof 18ml/minper1.73m2 versus no decline) associated with an adjusted hazard ratio of ESRDof 2.28 (95{\%} confidence interval, 1.88 to 2.76). In contrast, a current EGFR of 30 versus 50 ml/min per 1.73m2 (a difference of 20 ml/min per 1.73 m2) associated with an adjusted hazard ratio of 19.9 (95{\%} confidence interval, 13.6 to 29.1). Past decline contributed more to the absolute risk of ESRD at lower than higher levels of current EGFR. In conclusion, during a follow-up of 2 years, current EGFR associates more strongly with future ESRD risk than the magnitude of past EGFR decline, but both contribute substantially to the risk of ESRD, especially at EGFR,30ml/min per 1.73m2.",
author = "Csaba Kovesdy and Josef Coresh and Ballew, {Shoshana H.} and Mark Woodward and Adeera Levin and Naimark, {David M.J.} and Joseph Nally and Dietrich Rothenbacher and Benedicte Stengel and Kunitoshi Iseki and Kunihiro Matsushita and Levey, {Andrew S.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1681/ASN.2015060687",
language = "English (US)",
volume = "27",
pages = "2447--2455",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Past decline versus current EGFR and subsequent ESRD risk

AU - Kovesdy, Csaba

AU - Coresh, Josef

AU - Ballew, Shoshana H.

AU - Woodward, Mark

AU - Levin, Adeera

AU - Naimark, David M.J.

AU - Nally, Joseph

AU - Rothenbacher, Dietrich

AU - Stengel, Benedicte

AU - Iseki, Kunitoshi

AU - Matsushita, Kunihiro

AU - Levey, Andrew S.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - EGFRis a robustpredictor ofESRDrisk.However, the prognostic informationgainedfromthepast trajectory (slope) beyondthat of the currentEGFRisunclear.Weexamined22cohorts todeterminethe associationofpast slopes and current EGFR level with subsequent ESRD. We modeled hazard ratios as a spline function of slopes, adjusting for demographic variables,EGFR,andcomorbidities.Weusedrandomeffectsmeta-analyses tocombineresults across studies stratified by cohort type.We calculated the absolute risk of ESRD at 5 years after the last EGFR using the weighted average baseline risk. Overall, 1,080,223 participants experienced 5163 ESRD events during a mean follow-up of 2.0 years. InCKDcohorts, a slope of26versus0ml/minper 1.73m2 per year over the previous 3 years (adeclineof 18ml/minper1.73m2 versus no decline) associated with an adjusted hazard ratio of ESRDof 2.28 (95% confidence interval, 1.88 to 2.76). In contrast, a current EGFR of 30 versus 50 ml/min per 1.73m2 (a difference of 20 ml/min per 1.73 m2) associated with an adjusted hazard ratio of 19.9 (95% confidence interval, 13.6 to 29.1). Past decline contributed more to the absolute risk of ESRD at lower than higher levels of current EGFR. In conclusion, during a follow-up of 2 years, current EGFR associates more strongly with future ESRD risk than the magnitude of past EGFR decline, but both contribute substantially to the risk of ESRD, especially at EGFR,30ml/min per 1.73m2.

AB - EGFRis a robustpredictor ofESRDrisk.However, the prognostic informationgainedfromthepast trajectory (slope) beyondthat of the currentEGFRisunclear.Weexamined22cohorts todeterminethe associationofpast slopes and current EGFR level with subsequent ESRD. We modeled hazard ratios as a spline function of slopes, adjusting for demographic variables,EGFR,andcomorbidities.Weusedrandomeffectsmeta-analyses tocombineresults across studies stratified by cohort type.We calculated the absolute risk of ESRD at 5 years after the last EGFR using the weighted average baseline risk. Overall, 1,080,223 participants experienced 5163 ESRD events during a mean follow-up of 2.0 years. InCKDcohorts, a slope of26versus0ml/minper 1.73m2 per year over the previous 3 years (adeclineof 18ml/minper1.73m2 versus no decline) associated with an adjusted hazard ratio of ESRDof 2.28 (95% confidence interval, 1.88 to 2.76). In contrast, a current EGFR of 30 versus 50 ml/min per 1.73m2 (a difference of 20 ml/min per 1.73 m2) associated with an adjusted hazard ratio of 19.9 (95% confidence interval, 13.6 to 29.1). Past decline contributed more to the absolute risk of ESRD at lower than higher levels of current EGFR. In conclusion, during a follow-up of 2 years, current EGFR associates more strongly with future ESRD risk than the magnitude of past EGFR decline, but both contribute substantially to the risk of ESRD, especially at EGFR,30ml/min per 1.73m2.

UR - http://www.scopus.com/inward/record.url?scp=85013160277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013160277&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015060687

DO - 10.1681/ASN.2015060687

M3 - Article

VL - 27

SP - 2447

EP - 2455

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -